Sentiment for Pfizer Inc (NYSE:PFE)
Pfizer Inc (NYSE:PFE) institutional sentiment decreased to 0.78 in Q2 2018. Its down -0.11, from 0.89 in 2018Q1. The ratio fall, as 630 investment managers started new and increased equity positions, while 806 sold and reduced positions in Pfizer Inc. The investment managers in our partner’s database now own: 3.98 billion shares, down from 4.01 billion shares in 2018Q1. Also, the number of investment managers holding Pfizer Inc in their top 10 equity positions was flat from 130 to 130 for the same number . Sold All: 52 Reduced: 754 Increased: 518 New Position: 112.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $248.97 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 10.88 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
The stock decreased 1.03% or $0.45 during the last trading session, reaching $43.07. About 16.30M shares traded. Pfizer Inc. (NYSE:PFE) has risen 19.90% since November 14, 2017 and is uptrending. It has outperformed by 4.28% the S&P500.
Northeast Financial Consultants Inc holds 14.82% of its portfolio in Pfizer Inc. for 1.33 million shares. New England Professional Planning Group Inc. owns 224,595 shares or 10.47% of their US portfolio. Moreover, Stuyvesant Capital Management has 9.25% invested in the company for 136,875 shares. The Ohio-based Cincinnati Casualty Co has invested 7.67% in the stock. Clark Estates Inc Ny, a New York-based fund reported 1.19 million shares.
Since January 1, 0001, it had 0 insider purchases, and 4 insider sales for $2.80 million activity.
Pfizer Inc. (NYSE:PFE) Ratings Coverage
Ratings analysis reveals 43% of Pfizer’s analysts are positive. Out of 7 Wall Street analysts rating Pfizer, 3 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $37 while the high is $4500. The stock’s average target of $42.29 is -1.81% below today’s ($43.07) share price. PFE was included in 9 notes of analysts from June 7, 2018. The company was maintained on Tuesday, November 6 by Citigroup. The stock has “Overweight” rating by Morgan Stanley on Thursday, August 23. Barclays Capital maintained the shares of PFE in report on Thursday, August 23 with “Equal-Weight” rating. Credit Suisse maintained it with “Neutral” rating and $40 target in Wednesday, August 1 report. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, June 7. As per Wednesday, August 1, the company rating was maintained by Bank of America. The firm has “Neutral” rating by Credit Suisse given on Wednesday, October 31. The stock of Pfizer Inc. (NYSE:PFE) has “Outperform” rating given on Wednesday, August 1 by BMO Capital Markets. The firm has “Market Perform” rating given on Thursday, November 1 by BMO Capital Markets.
More important recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on November 01, 2018, also Seekingalpha.com published article titled: “FDA OKs Pfizer’s lorlatinib for lung cancer”, Seekingalpha.com published: “Evaluating Pfizer’s Growth Plans And Valuation” on November 01, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) was released by: Seekingalpha.com and their article: “Pfizer loses Lyrica patent fight” with publication date: November 14, 2018.